Vical is halting development of its experimental skin cancer drug Allovectin, its most advanced treatment, based on the findings of a late-stage study. The drug failed to significantly outperform chemotherapy in overall survival and reductions in tumor size in advanced melanoma patients. Vical will focus its resources on development of infectious disease vaccines, CEO Vijay Samant said.

Full Story:

Related Summaries